The protein CSN6 has been correlated with poor survival among patients with colorectal cancer, according to an
MD Anderson study published in the medical journal Cancer Cell.
Researchers found CSN6, a subunit of a protein complex known as COP9 signalosome, is overexpressed in colorectal cancer tissue samples. The finding could be significant in the search for improved and alternative treatment strategies for colorectal cancer.
"CSN6 is a biomarker that's elevated in colon cancer and leads to worse recurrence-free survival," said Mong-Hong Lee, Ph.D., professor of Molecular and Cellular Oncology. "This occurs when CSN6 is deregulated through a series of cellular signaling pathways."
The study was funded by the National Institutes of Health, the Susan G. Komen Breast Cancer Foundation, the Ministry of Science and Technology of China, the Program of Introducing Talents of Discipline to Universities and the International S&T Cooperation Program of China.